The Hospital of the University of Pennsylvania is the flagship hospital of Penn Medicine and is located in the University City section of West Philadelphia. It is consistently ranked as one of the top hospitals in the United States.

There are 776 beds in University of Pennsylvania Health System.

During the past decade, University of Pennsylvania Health System conducted 102 clinical trials. In the 10-year time frame, 102 clinical trials started and 49 clinical trials were completed, i.e. on average, 48% percent of trials that started reached the finish line to date. In the past 5 years, 46 clinical trials started and 29 clinical trials were completed. i.e. 63% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Pennsylvania Health System" #1 sponsor was "University of Pennsylvania" with 44 trials, followed by "Abramson Cancer Center at Penn Medicine" with 6 trials sponsored, "Gilead Sciences" with 6 trials sponsored, "Incyte Corporation" with 6 trials sponsored and "Hoffmann-La Roche" with 6 trials sponsored. Other sponsors include 89 different institutions and companies that sponsored additional 74 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Pennsylvania Health System" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 10 trials as a collaborator, "University of Pennsylvania" with 4 trials as a collaborator, "National Cancer Institute (NCI)" with 3 trials as a collaborator, "Patient-Centered Outcomes Research Institute" with 3 trials as a collaborator and "University of Arizona" with 3 trials as a collaborator. Other collaborators include 98 different institutions and companies that were collaborators in the rest 98 trials.

According to Clinical.Site data, the most researched conditions in "University of Pennsylvania Health System" are "Atrial Fibrillation" (4 trials), "Cardiovascular Diseases" (4 trials), "Colorectal Cancer" (4 trials), "Heart Failure" (4 trials) and "Ovarian Cancer" (4 trials). Many other conditions were trialed in "University of Pennsylvania Health System" in a lesser frequency.

Most popular intervention types in "University of Pennsylvania Health System" are "Drug" (79 trials), "Behavioral" (27 trials), "Device" (23 trials), "Other" (23 trials) and "Biological" (11 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Pembrolizumab" (4 trials), "Epacadostat" (3 trials), "Mitapivat" (3 trials) and "Paclitaxel" (3 trials). Other intervention names were less common.

The vast majority of trials in "University of Pennsylvania Health System" are 140 trials for "All" genders, 18 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 44 active trials in "University of Pennsylvania Health System". 1 are not yet recruiting, 20 are recruiting, 21 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 93 completed trials in University of Pennsylvania Health System, undefined suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in University of Pennsylvania Health System, 14 "Phase 1" clinical trials were conducted, 37 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 57 trials that are defined as “Not Applicable".